Section Arrow
Quote
HRMY.NASDAQ
- Harmony Biosciences Holdings
Quotes are at least 15-min delayed:2026/07/06 00:34 EDT
Regular Hours
Last
 37.26
+1.26 (+3.50%)
Day High 
37.4 
Prev. Close
36 
1-M High
36.64 
Volume 
1.01M 
Bid
33
Ask
37.95
Day Low
35.92 
Open
36.11 
1-M Low
30.7 
Market Cap 
2.08B 
Currency 美元 
P/E 14.52 
%Yield -- 
10-SMA 34.64 
20-SMA 34.17 
50-SMA 32.36 
52-W High 40.87 
52-W Low 25.52 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.48/4.15
Enterprise Value
2.23B
Balance Sheet
Book Value Per Share
15.72
Cash Flow
Cash Flow Yield
0.16
Income Statement
Total Revenue
582.02M
Operating Revenue Per Share
9.36
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc0.1425+0.0277+24.13%-- 
PPCBPropanc Biopharma Inc.1.77+0.33+22.92%0PE
RXRXRecursion Pharmaceuticals3.8+0.13+3.54%-- 
IOVAIovance Biotherapeutics4.31+0.34+8.56%-- 
SLSSELLAS Life Sciences Group14.98+1.71+12.89%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), andEPX-200 (lorcaserin), among others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.